Table 1. Clinical characteristics of 59 patients with stage I anaplastic Wilms tumor in the present study

Characteristics	FAWT	Р	IR-non-AWT	Р	DAWT
Number of patients	19 (32.2%)		818		40 (67.8%)
Median age at diagnosis,	3.32 (1.32-12.61)	0.1	2.58 (0.1 - 16.6)	<.00001	4.72 (0.84-9.07)
years (range)					
Gender					
Male	11 (57.9%)		389 (47.6%)		17 (42.5%)
Female	8 (42.1%)		429 (52.4%)		23 (57.5%)
Lymph nodes sampled					
Yes	16 (84.2%)		-		39 (97.5%)
No	3 (16.8%)		-		1 (2.5%)

FAWT - focal anaplasia Wilms tumor; DAWT - diffuse anaplasia Wilms tumor

IR-non-AWT - intermediate-risk non-anaplastic Wilms tumor

Table 2. Outcomes of patients with stage I FAWT and DAWT in different studies

	No of							
Study patients		FAWT		DAWT		IR-non-AWT	IR-non-AWT	
	(FA / DA)	EFS (%, 95% CI)	OS (%, 95% CI)	EFS (%, 95% CI)	OS (%, 95% CI)	EFS (%, 95% CI)	OS (%, 95% CI)	
Present study*	19 / 40	87 (72 - 100)	100	85 (74 - 98)	93 (85 - 100)	91 (89 - 93)	98 (97 - 99)	
SIOP 6&9 [4]	7 / 16	86	100	69	75	-	-	
NWTS-5 [12]	10 / 19	67.5 (16.2 - 91.9)	88.9 (43.3 - 98.4)	68.4 (42.8 - 84.4)	78.9 (53.2 - 91.5)	-	-	
AREN0321 [13]	8 / 10	100	100	100	100	-	-	
"Non-COG" [11]	- / 95	-	-	81.7 (73.9 - 90.3)	92.9 (87.6 - 98.6)	-	-	

FAWT - focal anaplastic Wilms tumor; DAWT - diffuse anaplasia Wilms tumor; IR-non-AWT - intermediate-risk non-anaplastic Wilms tumour

EFS - event-free survival; OS - overall survival

<sup>\*</sup> the only study where treatment of patients with FAWT and DAWT was different

Table 3. Comparison of treatment of patients with stage I anaplastic Wilms tumour in different studies

Study	Treatment	Drugs	Length of	Flank
	regimen	used	chemotherapy (wk)	radiation
SIOP 6&9	SIOP 6 & 9	VA + VAD	21/42* and 21/25**	No
NWTS-5	EE-4A	VA	18	No
AREN0321	DD-4A	VAD	25	Yes
"Non-COG"	UKW3 / SIOP 2001	VAD	31	No
Present study	SIOP 2001	VA (FAWT); VAD (DAWT)	8 (FAWT); 31 (DAWT)	No

<sup>\*</sup>in SIOP 6, postoperative chemotherapy randomized to 17 and 38 weeks;

VA = vincristine, adriamycin; VAD = vincristine, adriamycin, doxorubicin

<sup>\*\*</sup> in SIOP 9, preoperative chemotherapy randomized to 4 and 8 weeks

<sup>&</sup>quot;Non-COG" - only patients with DAWT analyzed